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Abstract.
Background: Currently there are no known cures and few effective treatments for mitochondrial disorders. It is also true there
is a lack of knowledge about suitable clinician rated outcomes and how these change over time in this patient cohort.
Objective: We sought to evaluate the validity and responsiveness to change of clinician rated outcome measures in patients with
m.3243A>G-related mitochondrial disease.
Methods: We assessed the six minute timed walk (6MTW), 10 meter walk / test (10MWT), Timed up and Go (TUG) and the
5 times sit to stand (5XSTS), in 18 patients (12 sedentary controls), at baseline and a subgroup of 10 control-matched patients
following a 16-week structured aerobic exercise intervention program.
Results: All outcome measures assessed were valid and able to differentiate between patients and controls. Disease severity,
as measured by the Newcastle Mitochondrial Disease Adult Scale, correlated with TUG (r = 0.54, p = 0.020) and 10MWT
(r = 0.47, p = 0.050). Receiver Operating Curve analysis revealed 5XSTS to be the most responsive measure (AUC 0.931; 95%
CI 0.84–1.00) with responsiveness to change, post intervention, emulating disease burden variance.
Conclusions: The 5XSTS can be used to discriminate between mitochondrial patients and sedentary controls with high accuracy.
The 10MWT and TUG may serve as suitable and clinically relevant clinician rated measures to track disease progression and
assess intervention.
INTRODUCTION
Mitochondrial disorders are the most prevalent
group of inherited neurometabolic diseases with sig-
nificant morbidity and mortality. Recording the natural
history and evaluating therapeutic interventions in
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this group of diseases has proven problematic due to
their inherent genotypic and phenotypic heterogene-
ity, multi-system involvement, and the historical lack
of validated outcome measures meaningful to both
clinicians and patients. Comprehensive natural history
data and disease progression are now being captured
in specialist centres using the Newcastle Mitochon-
drial Disease Adult Scale (NMDAS) [1]. NMDAS is
a validated rating scale and consists of four domains
that incorporate clinician rated measures (system spe-
cific involvement), patient rated measures (current
function, quality of life) and a combination of both
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(current clinical assessment). Although a consistent
and reliable scale, its use is often limited to highly spe-
cialised centres with expertise in the care of patients
with mitochondrial disease. However, quick and eas-
ily applicable clinician rated outcome measures might
also prove useful in a wider range of clinical settings.
We aimed to 1) assess four clinician rated outcome
measures that have been validated and widely used in
other neuromuscular disorders; 2) determine if any of
these measures would be robust, responsive, and valid
and potentially serve as an additional, easily performed
clinician rated measure of disease severity in patients
with mitochondrial disease.
MATERIALS AND METHODS
Subjects and study design
Eighteen adults with mitochondrial disease due to
the m.3243A>G MELAS mutation were recruited
from consecutive attendees at a specialist outpa-
tient clinic and formed part of a larger study into
cardiac adaptations to exercise in mitochondrial dis-
ease [2] (Supplementary table 1). Twelve sedentary
age-matched control subjects were also recruited
through local advertisement. Ten patients and 10
control subjects were invited to participate in a 16
week structured aerobic exercise program, cycling
3 times a week (30 minutes/session) and achiev-
ing a heart rate corresponding to 70–80% of the
peak exercise test as previously reported [2]. All
clinician rated measures were performed pre and
post intervention as detailed below by a single,
experienced assessor were appropriate (5XST, TUG,
10MWT, 6MWT: JN; NMDAS: GSG). Institutional
ethical approval and written informed consent were
obtained.
Demographic and clinical measures
Assessment of disease burden, cardiopulmonary
fitness, habitual physical activity levels and
muscle strength
Disease burden was assessed using the NMDAS, a
validated rating system [1]; whilst mtDNA mutation
load was determined in urinary epithelial cells [3].
Cardiopulmonary exercise testing was performed in all
participants at baseline and 20 subjects (10 mitochon-
drial disease; 10 controls) post intervention. Physical
activity and energy expenditure were assessed at base-
line using a multi-sensor array (SenseWear Pro3,
Bodymedia Inc, Pennsylvania, USA) and completion
of the International Physical Activity Questionnaire
(IPAQ) for 7 days [4]. Hip flexor and extensor strength
measurements were performed by a single investiga-
tor (JN) using an isokinetic dynamometer (Cybex,
HUMAC®/NORM, NY, USA) at a speed of 60◦
per second. Participants underwent familiarization
with six sub-maximal contractions and then per-
formed six maximal repetitions with consistent verbal
encouragement.
Clinician rated outcome measures
All subjects undertook five times sit to stand
(5XSTS), Timed up and Go test (TUG), timed 10 meter
walk test (10MWT) and the six minute timed walk
(6MTW)[5, 6].
Statistical analysis
Data are presented as mean ± SD for continu-
ous data. Continuous data were tested for normality
using the Kolmogrov-Smirnov test, and group compar-
isons at baseline were made using two-tailed Student’s
t-tests or Mann-Whitney U tests. Correlations were
executed as two-tailed tests using Pearson’s or Spear-
man’s method dependent on normality. Pre and post
intervention data were analyzed using paired t-tests
or a Related-Samples Wilcoxin Signed Rank Test as
appropriate. All analysis was performed using SPSS
version 19 (SPSS Inc, Chicago, Illinois). Statistical sig-
nificance was assumed at p < 0.05. Accuracy of tests
was determined by Receiver Operating Curve analy-
sis. The proposed study sample size was calculated as
follows: nine participants will have 80% power at 0.05
alpha to detect a mean change of 0.15 in peak oxygen
consumption post exercise intervention, as previously
shown [7].
RESULTS
Thirty participants completed baseline evalua-
tions (18 patients; 12 controls) and 20 participants
(10 patients) completed all assessments post inter-
vention (Table 1). Demographic and clinical details
of mitochondrial participants are summarised in
supplementary Table 1. No patients with mitochondrial
disease demonstrated signifcant cognitive or respi-
ratory dysfunction. All patients remained clinically
stable throughout the study, and there were no changes
in medication. 5XSTS and TUG showed significant
differences between patients and controls (Table 1).
Disease burden determined by total NMDAS correlated
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Table 1
Disease burden, activity levels, physiological capacity and functional capacity of patients and control subjects pre (n = 30) and post aerobic
exercise (n = 20) intervention
Domain Variable m.3243A>G m.3243A>G p value a Controls Controls p value a
(Mean ± SD) (Mean ± SD) (Mean ± SD) (Mean ± SD)
Baseline Post exercise Baseline Post exercise
(n = 18; 9 F) (n = 10; 4 F) (n = 12; 5 F) (n = 10; 4 F)
Disease Severity NMDAS 16 ± 8 15 ± 8 0.539 n/a n/a n/a
Activity level Energy expenditure (calories) 2097 ± 547∗ n/a n/a 2602 ± 480 n/a n/a
Steps taken per day 7819 ± 4859 n/a n/a 10,094 ± 3841 n/a n/a
Physiological Peak exercise capacity (ml/kg/min) 20.8 ± 5.8∗∗ 24.8 ± 8.9 0.009 27.9 ± 6.6 30.4 ± 5.6 0.073
capacity Anaerobic threshold (ml/kg/min) 13.0 ± 4.1∗ 16.5 ± 6.4 0.014 16.3 ± 4.6 18.7 ± 3.9 0.017
Peak workload (w/kg) 1.5 ± 0.4∗∗ 1.7 ± 0.6 0.09 2.2 ± 0.5 2.5 ± 0.5 0.002
Arterial venous difference (ml O2 /dl) 9.4 ± 2.7 10.5 ± 3.1 0.025 11.2 ± 4.8 11.8 ± 1.8 0.205
Hip flexor strength (nm/kg) 0.7 ± 0.4∗ 0.7 ± 0.3 0.859 1.1 ± 0.5 1.1 ± 0.5 0.283
Functional 5 times sit to stand (secs) 11.3 ± 2.5∗∗ 10.6 ± 4.5 0.631 7.2 ± 1.6 6.9 ± 1.5 0.832
capacity Timed up and go (secs) 7.9 ± 1.5∗∗ 7.6 ± 1.3 0.68 6.6 ± 0.5 6.8 ± 0.6 0.221
10 meter timed walk (secs) 7.4 ± 1.2 7.1 ± 1.3 0.842 6.7 ± 0.6 6.6 ± 0.8 0.796
6 minute walk distance (m) 486 ± 107 471 ± 68 0.63 513 ± 52 539 ± 54 0.051
ap value represents the within group comparison of paired before and follow up time points. ∗p < 0.05 and ∗∗p < 0.01 for patients vs controls at
equivalent baseline time points.
with 10MWT (r = 0.47, p = 0.050) and TUG(r = 0.54,
p = 0.021), but not with VO2 peak (r = −0.372,
p = 0.128); peak workload (r = −0.306, p = 0.217);
5XSTS (r = 0.197, p = 0.432); 6MTW (r = −0.252,
p = 0.313);Hipflexionstrength (r = −0.203,p = 0.469);
Hip extension strength r = −0.0258, p = 0.354).
Proximal muscle strength correlated with all exer-
cise parameters and the 6MTW (Supplementary
Table 2). 5XSTS was the most responsive (Area Under
the Curve (AUC) 0.94;95% CI 0.84–1.00) outcome
measure to discern patients from controls. Walk assess-
ments showed high specificity (10MWT; 92%) and
greatest sensitivity (6MTW; 100%) (Fig. 1). Both
groups showed improvements in exercise capacity
post exercise intervention (Table 1) (Supplementary
Figure 1).
DISCUSSION
This preliminary study used both formal exercise
testing and other clinician rated outcome measures to
assess exercise capacity and physical performance of
patients harbouring the m.3243A>G MELAS muta-
tion. These measures have been shown to be reliable
and sensitive in many neurological conditions but have
not been validated to our knowledge in patients with
mitochondrial disease. Moreover, as these measures
are non-invasive and are quick and easy to admin-
ister, their use could prove beneficial in furthering
our understanding of the impact of these diseases on
patients over time, enable detection of deterioration
and facilitate standardized evaluation of potential ther-
apeutic interventions, which is currently lacking [8].
All clinician rated outcome measures assessed showed
good sensitivity and specificity. Consistent with a
previous case–control study in patients with mitochon-
drial disease [9], peak exercise and workload capacity
were significantly decreased in patients compared to
untrained, sedentary controls (Table 1; Supplementary
Figure 1). The congruity of results between walking
tests and exercise capacity is a convincing argument
for revision of the exercise assessments requested in
clinical practice, substituting formal exercise testing
with simple, inexpensive and clinically relevant walk-
ing tests.
Muscle strength was reduced by 50% in patients
compared to controls. Although strength was signifi-
cantly lower, and correlated with the 6MTW only, there
was no correlation with disease severity, as assessed
by NMDAS; again suggesting skeletal myopathy is
not the primary impairment in our patient cohort,
and confirming that muscle power can be markedly
reduced without affecting the clinician rated out-
comes under investigation. Proximal muscle strength
strongly correlated to peak exercise capacity and this
should be taken into account when formally test-
ing exercise capacity in patients with mitochondrial
disease.
STUDY LIMITATIONS
A wide range of clinician rated outcome measures
currently exist that if carried out would be too burden-
some for patients. Therefore, in this study we selected
measures that related to symptoms commonly experi-
enced in patients with mitochondrial disease. As this
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Fig. 1. Area under the curve plots for functional outcome measures and peak exercise capacity. Cut off chosen at the point of maximum
accuracy. Peak VO2 (sensitivity 67%, specificity 83%, accuracy 78% (p = 0.009); sit to stand (sensitivity 94%, specificity 75%, accuracy 89%
(p<0.001); timed up and go (sensitivity 72%, specificity 83%, accuracy 75% (p = 0.009); 10MWT(sensitivity 61%, specificity 92%, accuracy
72% (p = 0.057); 6MTW (sensitivity 100%, specificity 44%, accuracy 81% (p = 0.103).
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investigation formed part of a larger study into cardiac
adaptations to exercise in mitochondrial disease [2]
numbers involved were small, and limited in respects
of genotypic and phenotypic heterogeneity. Despite
these constraints, the study demonstrated that relevant
and easy to perform clinician rated outcome measures
can robustly discriminate between patient and con-
trol subjects, and their magnitude of change correlated
with disease severity (NMDAS), following an exercise
intervention.
CONCLUSION
Measuring the multitude of symptoms present
in patients with mitochondrial disease can be time
consuming and expensive. Clinician rated outcome
measures are global assessments that are easily trans-
ferred to the clincal and home environment. Our
findings are promising, but future work is required to
assess how valid these measures are between differ-
ent sites and within a larger cohort of patients with
phenotypic and genotypic heterogeneity. In this pre-
liminary study we have demonstrated that the 5XSTS
is the most robust measure that is able to discrimi-
nate between patients and controls; whilst 10MWT and
TUG serve as potential measures to track disease pro-
gression and assess potential interventions in patients
with mitochondrial disease.
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